10-Q: Plus Therapeutics Reports Second Quarter 2024 Results, Navigates Financial Challenges

Plus Therapeutics reported its second quarter 2024 results, highlighting ongoing clinical trials and a recent private placement, while also addressing concerns about its financial position and Nasdaq listing compliance.

Summary

• Plus Therapeutics reported a net loss of $2.94 million for the three months ended June 30, 2024, and a net loss of $6.2 million for the six months ended June 30, 2024.
• The company's accumulated deficit reached $486.7 million as of June 30, 2024.
• Operating activities used $5.7 million in cash for the six months ended June 30, 2024.
• The company received approximately $7.3 million in gross proceeds from a private placement in May 2024.
• The company is developing targeted radiotherapeutics for central nervous system cancers, with lead candidate rhenium (186 Re) obisbemeda in clinical trials.
• The company acquired the CNSide diagnostic portfolio from Biocept in April 2024 for $400,000.
• The company is seeking partnering opportunities for the CNSide IP and expects a commercial launch in the fourth quarter of 2024.
• The company received a $3 million grant from the Department of Defense for pediatric brain cancer research.
• The company is working to regain compliance with Nasdaq listing requirements after receiving a notice of non-compliance due to insufficient stockholders' equity.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and strategic acquisitions, the company's financial situation and Nasdaq listing compliance issues raise significant concerns. The overall sentiment is cautiously negative due to the financial risks.

Positives

• The company's lead drug candidate, rhenium (186 Re) obisbemeda, has shown promising results in clinical trials for GBM and LM.
• The company has secured a $3 million grant from the Department of Defense for pediatric brain cancer research.
• The company has successfully raised capital through a private placement in May 2024.
• The company has paid off its term loan, removing a significant debt obligation.
• The company has acquired the CNSide diagnostic portfolio, which is expected to generate revenue in the near future.
• The company has established a robust supply chain for its products.

Negatives

• The company has incurred significant net losses and has an accumulated deficit of $486.7 million.
• The company's operating activities used $5.7 million in cash for the six months ended June 30, 2024.
• The company received a notice from Nasdaq for non-compliance with listing requirements due to insufficient stockholders' equity.
• The company's ability to continue as a going concern is in doubt.
• The company may need to significantly reduce or curtail its research and development and other operations if sufficient capital is not raised.
• The company has a negative working capital of $9.4 million.

Risks

• The company's ability to raise additional capital is uncertain, which could impact its operations and ability to maintain Nasdaq listing.
• The company's clinical trials are subject to risks and uncertainties, and results may not be favorable.
• The company's product candidates are in early stages of development and may not receive regulatory approvals.
• The company faces competition in the radiotherapeutics and oncological medicine fields.
• The company's ability to integrate and monetize acquired assets, such as the CNSide portfolio, is not guaranteed.
• The company's reliance on grant funding and external sources of capital creates financial vulnerability.
• The company's new margin loan facility with Pershing LLC has the effect of limiting the Companys use of cash and marketable securities.
• The company's 188 RNL-BAM product will be regulated as a medical device, which may result in additional regulatory and other risks.

Future Outlook

The company expects to continue advancing its clinical programs, including the ReSPECT-GBM and ReSPECT-LM trials, and plans to submit a pediatric brain tumor IND in the third quarter of 2024. The company also anticipates a commercial launch of the CNSide diagnostic portfolio in the fourth quarter of 2024. The company will continue to seek additional capital to fund its operations.

Management Comments

• The company is currently evaluating and developing its business plan for developing the CNSide diagnostic portfolio alongside our lead radiotherapeutic candidate, rhenium (186 Re) obisbemeda.
• The company is seeking partnering opportunities for the CNSide IP.
• The CNSide TM is on track for commercial launch as soon as the fourth quarter of 2024.
• The company plans to initiate dosing in Cohort 6 of the ReSPECT-LM trial in the second quarter of 2024, pending Data Safety Monitoring Board (DSMB) approval.
• The company is planning a new multiple dosing ReSPECT-LM clinical trial in late 2024 or early 2025.

Industry Context

The company is operating in the competitive radiotherapeutics and oncology space, focusing on difficult-to-treat cancers with unmet medical needs. The company's targeted approach to radiation therapy, using nanoliposomes and microspheres, is aimed at improving efficacy and reducing toxicity compared to traditional methods like external beam radiation. The acquisition of the CNSide diagnostic portfolio aligns with the trend of combining diagnostics and therapeutics for personalized medicine.

Comparison to Industry Standards

• The median overall survival of 13 months in the Phase 2 ReSPECT-GBM trial is a significant improvement compared to the 8 months typically seen with bevacizumab monotherapy, a standard of care for recurrent GBM.
• The company's ability to deliver up to 740 Gy of absorbed radiation to tumor tissue without significant toxicities is a notable achievement compared to the typical 30-35 Gy delivered by external beam radiation therapy for recurrent GBM.
• The company's approach of using convection-enhanced delivery (CED) and intraventricular brain catheters for targeted drug delivery is consistent with advanced techniques in neuro-oncology.
• The company's focus on rare and difficult-to-treat cancers aligns with the industry trend of developing therapies for niche markets with high unmet needs.
• The company's use of a synthetic control arm platform, in collaboration with Medidata, is an innovative approach to clinical trial design, potentially reducing the need for traditional control groups.

Related Party Transactions

• Certain of the company's directors and executive officers participated in the May 2024 private placement.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures if the company fails to secure additional funding.
• Patients may benefit from the company's innovative therapies, but clinical trial outcomes are uncertain.
• Creditors face the risk of non-payment if the company's financial situation worsens.
• Suppliers may be impacted by potential changes in the company's operations and spending.

Next Steps

• The company plans to continue enrollment in the ReSPECT-GBM Phase 2b trial, with a target for full enrollment by the end of 2024.
• The company plans to initiate dosing in Cohort 6 of the ReSPECT-LM Phase 1/2a trial, pending DSMB approval.
• The company plans to submit a pediatric brain tumor IND in the third quarter of 2024.
• The company plans a commercial launch of the CNSide diagnostic portfolio in the fourth quarter of 2024.
• The company plans a new multiple dosing ReSPECT-LM clinical trial in late 2024 or early 2025.
• The company will continue to seek additional capital from financing alternatives and other sources.

Key Dates

Keywords

radiotherapeutics, glioblastoma, leptomeningeal metastases, rhenium obisbemeda, clinical trials, CNSide, private placement, Nasdaq, going concern, cancer, pediatric brain cancer, warrants, biotech, oncology